Specialty Hub

In-depth learning materials and relevant resources by areas of interest.

Welcome:

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event

In this section

Cardiology

Assorted resources on conditions connected to Cardiology.

Dermatology

Latest information on diseases in Dermatology.

Endocrinology

A detailed look at conditions connected to Endocrinology.

Gastroenterology and Hepatology

In-depth material on Gastroenterology and Hepatology.

Haematology

Assorted resources on conditions connected to Haematology.

Immunology

Immunology, the immune system and immune-mediated diseases.

Infectious Diseases

A detailed look at conditions connected to Infectious Diseases.

Nephrology

Assorted resources on conditions related to Nephrology.

Neurology (CNS) and Pain

Learning materials and guidelines on Neurology (CNS) and Pain.

Oncology

A detailed look at conditions connected to Oncology.

Ophthalmology

Assorted resources on conditions connected to Ophthalmology.

Respiratory

In-depth material on Respiratory conditions.

Rheumatology

Latest information on diseases in Rheumatology.

Urology

Learning materials and guidelines on Urology.

Latest news

Drug news

FDA grants accelerated approval to Tivdak for the treatment of metastatic cervical cancer.

Seagen Inc and Genmab A/S announced that the FDA has granted accelerated approval to Tivdak (tisotumab vedotin-tftv), the first and only approved antibody-drug conjugate (ADC) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

1 mins

Drug news

Mirati Therapeutics presents positive clinical data with adagrasib as monotherapy and + cetuximab.

Mirati Therapeutics, Inc.,announced results from a cohort of the Phase 1/II KRYSTAL–1 study evaluating adagrasib at the 600mg BID dose as both monotherapy and in combination with cetuximab in patients with heavily pretreated colorectal cancer harboring a KRASG12C mutation.

1 min

Drug news

Skyrizi filed with FDA for moderate to severe Crohn's disease.

AbbVie has submitted an application to the FDA seeking approval for Skyrizi (risankizumab-rzaa) (600 mg intravenous (IV) induction and 360 mg subcutaneous (SC) maintenance therapy), an interleukin-23 (IL-23) inhibitor, for the treatment of patients 16 years and older with moderate to severe Crohn's disease.

1 min

See all news

You may be interested in...

Journal

Intralesional photodynamic therapy in hidradenitis suppurativa: Getting closer to the target

The successful treatment of hidradenitis suppurativa (HS) with intralesional photodynamic therapy (IL-PDT) has been previously reported in some case series published a few years ago. We present additional data and patient outcome for this form of PDT.

Journal

Adalimumab Induces a Wound Healing Profile in Patients with Hidradenitis Suppurativa by Regulating Macrophage Differentiation and Matrix Metalloproteinase Expression

Adalimumab (ADA) is the only Food and Drug Administration‒approved treatment for moderate-to-severe hidradenitis suppurativa, whereas etanercept and certolizumab-pegol have been shown to be ineffective, suggesting that the mechanism of action of ADA is distinct in hidradenitis suppurativa and may contribute to improved wound healing.

Journal

Serum high-sensitivity C-reactive protein, tumor necrosis factor-α, interleukin (IL)-1β, IL-17A and IL-23 levels in patients with hidradenitis suppurativa

Objectives: To assess the serum levels of proinflammatory cytokines TNF-α, IL-1β, IL-17A, IL-23 and high-sensitivity C-reactive protein (hs-CRP) in patients with HS and to evaluate the impact of treatment on cytokine levels.